Glaukos Presents Data at ASCRS, Highlights Corneal Cross-Linking Expansion
Event summary
- Glaukos will present multiple scientific abstracts at the ASCRS Annual Meeting in Washington, D.C., April 10-13, 2026.
- The company is sponsoring a symposium focused on Epioxa™, its FDA-approved epithelium-on corneal cross-linking treatment.
- Presentations will cover outcomes for glaucoma stents, a keratoconus screening device, and intracameral travoprost implants.
- Glaukos will exhibit at booth #407 during the ASCRS meeting.
The big picture
Glaukos's presence at ASCRS underscores its commitment to data-driven validation of its technologies, particularly in the competitive glaucoma and corneal health markets. The focus on Epioxa signals a strategic push beyond traditional MIGS, targeting a broader range of corneal disorders. The company’s expanding product portfolio, including iDose TR, positions it to capture a larger share of the $20 billion+ global ophthalmology market, but faces challenges in demonstrating long-term efficacy and securing reimbursement.
What we're watching
- Clinical Adoption
- The reception of the Epioxa symposium and the presented data will indicate the speed of adoption for this novel corneal cross-linking treatment among ophthalmologists.
- Pipeline Progress
- Continued data releases regarding the Trabecular Micro-Bypass Stents and intracameral implants will reveal the trajectory of Glaukos’ broader pipeline and its potential to disrupt glaucoma treatment paradigms.
- Reimbursement
- The long-term success of Epioxa and iDose TR will depend on securing favorable reimbursement rates from payers, which remains a key hurdle for innovative ophthalmic therapies.
Related topics